Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesLaboratory/PathologyBCBS Louisiana thrombosis testing Coverage Update …
    Ask Trek AI about this page
    Modifiedblue cross blue shield - louisianaPolicy AHS - M2041

    Venous and Arterial Thrombosis Risk Testing

    Customize your policy alerts

    Sign up for blue cross blue shield - louisiana Policy AHS - M2041 alerts

    Get alerted when Policy AHS - M2041 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Policy governing coverage and limitations for laboratory testing to evaluate inherited and acquired thrombophilias and related assays for venous and arterial thrombosis risk; applies to Blue Cross and Blue Shield of Louisiana members and providers requesting such testing.

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyVenous and Arterial Thrombosis Risk Testing
    Policy CodePolicy AHS - M2041
    Change TypeCoverage criteria updates and code removals (material and editorial changes)
    Effective DateSep 15, 2026
    Last ReviewSep 15, 2026
    Next Review DateSep 15, 2026
    Key ActionOrder protein C, protein S, and antithrombin III plasma testing only for specified clinical indications and perform testing ≥6 weeks after an acute event while the patient is off anticoagulants.
    SourceLink
    POLICY UPDATE CHANGES

    Removal of CC1.f. from coverage criteria following ACMG guideline update.

    Former CC1.d. edited for clarity.

    Removed assays timing note: 'Assays for clotting inhibitors amount and function should be performed prior to any molecular testing.'

    Removed CPT codes 81240, 81241, 81291, 81400, 81479, 0278U from the policy's code list.

    New CC6: activated protein C (aPC) resistance assay DOES NOT MEET COVERAGE CRITERIA.

    protein C/S/antithrombinCovered in specified clinical situations
    aPC resistanceNot covered — aPC assay
    pre-transplant DVTNot covered — pre-transplant DVT testing
    ≥6 weeksTiming recommendation
    ~20References cited
    09/15/2026Last revision

    Coverage Criteria

    inv-01: Covered — Protein C, Protein S, Antithrombin III

    Plasma testing for protein C deficiency, protein S deficiency, and antithrombin III deficiency MEETS COVERAGE CRITERIA when ANY one of the following applies:

    Covered indications for protein C/S/antithrombin testing: a) Individuals <50 years who have experienced any deep venous thrombosis (DVT) or pulmonary embolism (PE); b) Individuals with DVT in unusual sites (e.g., hepatic, mesenteric, or cerebral veins); c) Individuals with DVT and a strong family history of thrombotic disease; d) Individuals with DVT who are pregnant or who are taking oral contraceptives (OCs); e) First- and second-degree relatives of individuals who experienced a DVT before age 50; f) Targeted testing before the administration of oral contraceptives for individuals with a personal or family history of DVT; g) Pediatric individuals who have suffered a pediatric arterial ischemic stroke.

    inv-02: Covered — Special clinical presentations

    Specific covered situations (separate):

    Warfarin-induced skin necrosis / neonatal purpura fulminans: For individuals with warfarin-induced skin necrosis or for infants who develop neonatal purpura fulminans, plasma testing for protein C deficiency and protein S deficiency MEETS COVERAGE CRITERIA.

    inv-04: ACMG — Recommended testing indications for Factor V Leiden and prothrombin G20210A

    ACMG: Testing for Factor V Leiden and prothrombin G20210A is recommended when any of the following applies:

    ACMG recommended indications: VTE at unusual sites (such as cerebral and splanchnic venous thrombosis); VTE provoked by pregnancy or postpartum; VTE associated with use of oral contraceptives (OCs); personal history of VTE with a positive family history of thrombophilia in a first- or second-degree relative or one first-degree relative with VTE at a young age; individuals with low APC resistance activity.

    From ACMG guidance

    inv-05: ACMG — Suggested testing indications

    ACMG: Testing is suggested (may be considered) in these scenarios:

    ACMG suggested indications: Recurrent VTE; siblings of individuals known to be homozygous for FVL or prothrombin G20210A; asymptomatic pregnant individuals or those contemplating pregnancy or estrogen use who have a first-degree relative known to be homozygous or double heterozygote (FVL and prothrombin G20210A); asymptomatic pregnant individuals or those contemplating pregnancy with prior non-estrogen-related VTE or VTE provoked by a minor risk factor when knowledge of FVL or prothrombin G20210A status may alter pregnancy-related thromboprophylaxis.

    From ACMG guidance

    inv-06: AHA/ASA — Pediatric and timing guidance

    AHA/ASA: Recommendations regarding testing timing and pediatric considerations

    AHA/ASA timing and pediatric notes: Testing for thrombophilic abnormalities in children lacks adequately powered studies; non-DNA (protein) testing may need to be repeated when the child is older to ensure adult protein levels have been attained. Measurement of protein levels in the acute phase may be inaccurate and should be repeated after the acute event; protein C, protein S, and antithrombin testing should be deferred or repeated at least 4 to 6 weeks (and up to 6 months for some factors such as factor VIII) after the acute stroke or thrombotic event. For ordering, plasma tests should be performed at least six weeks after the acute thrombotic event and while the patient is not taking anticoagulants.
    AHA/ASA evaluation suggestion: A thrombophilia evaluation is considered helpful in every case of childhood arterial ischemic stroke, especially when there is no identifiable cause, a history of thrombosis, or a first-degree relative with thrombosis history.

    inv-07: ASH — Testing recommendations and limitations

    ASH: Recommendations on who to test and when (multiple conditional recommendations based on very low certainty)

    ASH conditional recommendations to test: Consider thrombophilia testing in select situations: patients with VTE provoked by nonsurgical major transient or hormonal risk factors; patients with cerebral (CVT) or splanchnic venous thrombosis when anticoagulation would otherwise be discontinued; individuals with family history of antithrombin/protein C/protein S deficiency when considering thromboprophylaxis for minor provoking factors; pregnant women with a family history of high-risk thrombophilia; selected ambulatory cancer patients with family history of VTE; and specific CVT and splanchnic thrombosis cases to guide anticoagulant duration.

    Multiple ASH conditional recommendations

    ASH recommendations to not test routinely: Strong recommendation against testing the general population before starting combined oral contraceptives (COCs); conditional recommendations against routine testing to guide anticoagulant duration in many unprovoked or surgically provoked VTE settings and other routine contexts.

    From ASH guidance

    inv-08: ACOG — Obstetric screening guidance

    ACOG: Recommendations on screening in obstetric contexts

    ACOG not recommended: Screening for inherited thrombophilias is not recommended for women with a history of fetal loss or adverse pregnancy outcomes (eg, abruption, preeclampsia, fetal growth restriction) because antepartum prophylaxis has insufficient evidence to prevent recurrence.

    ACOG 2018

    ACOG recommended tests for women with personal history of VTE: For women with a personal history of VTE, recommended screening tests include Factor V Leiden, prothrombin G20210A, antithrombin deficiency, protein S deficiency, and protein C deficiency.

    ACOG 2018 consensus

    inv-09: Coverage criteria revisions (summary) — revision notes

    Review/Revision History notes changes to coverage criteria (summary):

    CC changes: Revision actions documented: removal of CC1.f. following ACMG guideline updates; editing of former CC1.d. for clarity; addition of CC6 designating activated protein C (aPC) resistance assay DOES NOT MEET COVERAGE CRITERIA; removal of several CPT codes from the policy's code list as noted in revision history.

    See Review/Revision History for dates and rationale.

    Venous thrombosis risk testing for superficial venous thrombosis (including superficial thrombophlebitis and varicosities) DOES NOT MEET COVERAGE CRITERIA and is excluded from coverage.

    Activated protein C (aPC) resistance assay is explicitly listed as excluded: the policy states that the aPC resistance assay DOES NOT MEET COVERAGE CRITERIA, and this exclusion is recorded as new criterion CC6 in the Review/Revision History.

    Testing to assess deep vein thrombosis (DVT) risk as part of a pre-transplant evaluation is excluded because available published literature does not demonstrate that such testing is required or beneficial; therefore, pre-transplant DVT risk testing DOES NOT MEET COVERAGE CRITERIA.

    Prenatal testing and population screening for common thrombophilia variants are not indicated; the ACMG advises that prenatal testing and population screening are not recommended due to low penetrance, later age of onset, and lack of genotype-directed prophylaxis. Testing for MTHFR variants is not supported for thrombophilia assessment because it lacks correlation with adverse pregnancy outcomes.

    The policy explicitly records in the Review/Revision History (new CC6) that an aPC resistance assay DOES NOT MEET COVERAGE CRITERIA. Claims for this assay may be denied under the policy because it is not a covered service.

    Routine thrombophilia testing in clinical settings where there is no evidence that results will change management is not covered. Examples include routine pediatric testing without clinical indication and other situations lacking demonstrated benefit; such routine use is considered not medically necessary or does not meet coverage criteria.

    Routine thrombophilia testing to guide broad population decisions (for example, screening average-risk women prior to initiating combined oral contraceptives or hormone replacement therapy) is not recommended and is not supported by guideline bodies; thus such routine population-level screening is not covered.

    The policy designates the aPC resistance assay as not meeting coverage criteria (CC6). As such, use of the functional aPC resistance assay is considered not medically necessary for coverage under this policy.

    Covered Indications

    inv-41: Protein C, protein S, and antithrombin III plasma testing — covered with timing/specimen notes

    Plasma testing for protein C, protein S, and antithrombin III deficiency MEETS COVERAGE CRITERIA when ANY one of the listed indications is met; specimen timing and anticoagulant status requirements apply:

    Covered indications: See Covered — Protein C, Protein S, Antithrombin III (CC1): individuals <50 with DVT/PE; DVT at unusual sites; DVT with strong family history; DVT while pregnant or on OCs; first- or second-degree relatives of early-onset DVT; targeted testing before OCs when personal/family history of DVT; pediatric arterial ischemic stroke survivors.
    Timing and specimen considerations: Testing should be performed at least six weeks after the acute thrombotic event and while the patient is not taking anticoagulants; protein and other non-DNA tests may need repetition after recovery or when the patient is older (pediatric considerations).>= 6 weeks after acute event

    inv-42: Protein C and protein S testing — warfarin-induced skin necrosis or neonatal purpura fulminans

    Not Covered / Exclusions

    Not covered under this policy are: aPC resistance assays; testing to assess venous thrombosis risk for superficial venous thrombosis (including superficial thrombophlebitis and varicosities); and DVT risk testing performed as part of pre-transplant evaluations.

    The policy does not support routine MTHFR variant testing and advises against prenatal or population screening for common thrombophilia variants because these approaches lack clinical utility and do not inform genotype-directed prophylaxis.

    The activated protein C (aPC) resistance assay is explicitly stated as not meeting coverage criteria (CC6) in the policy and is therefore listed as not covered.

    Coding and Procedure Codes

    Applicable CPT/HCPCS Procedure Codesmixed
    No codes listed
    Example listed procedure codesCPT
    85300Clotting inhibitors or anticoagulants; antithrombin III, activity.
    85301Clotting inhibitors or anticoagulants; antithrombin III, antigen assay.
    85302Clotting inhibitors or anticoagulants; protein C, antigen.
    85303Clotting inhibitors or anticoagulants; protein C, activity.
    85305Clotting inhibitors or anticoagulants; protein S, total.
    85306Clotting inhibitors or anticoagulants; protein S, free.
    85307Activated Protein C (APC) resistance assay.
    CPT/Genetic codes removed in prior revisionCPT
    81240Removed from policy code list (previous genetic test code).
    81241Removed from policy code list (previous genetic test code).
    81291Removed from policy code list (previous genetic test code).
    81400Removed from policy code list (previous genetic test code).
    81479Removed from policy code list (previous genetic test code).
    0278URemoved from policy code list (removed 09/01/2023).
    inv-21: D-dimer threshold in hepatectomy study
    D-dimer threshold (hepatectomy study)> 20 μg/mL
    Study contextPost‑operative serum D‑dimer used to trigger CT imaging for VTE after hepatectomy (742 patients).
    Imaging triggerCT scan performed for patients with D‑dimer > 20 μg/mL in the study.
    inv-22: Estradiol serum level
    Recommended upper physiologic estradiol range100-200 pg/mL
    Context of recommendationEndocrine Society guidance for individuals receiving estrogen therapy (to avoid supraphysiological levels linked to increased VTE risk).

    Provider Actions and Prior Authorization

    Prior Authorization

    Clinical indication requirement — order only for listed indications

    Coverage for thrombophilia testing is limited to the clinical indications listed in the policy. Order plasma testing for protein C, protein S, and antithrombin III only when one of the covered scenarios applies (for example: individuals <50 years with DVT or PE; DVT at unusual sites such as hepatic, mesenteric, or cerebral veins; DVT with a strong family history; DVT in pregnancy or while taking oral contraceptives; first- or second-degree relatives of someone with DVT before age 50; targeted testing before OCs when there is a personal or family history of DVT; pediatric arterial ischemic stroke).

    • Covered indications include: age <50 with DVT/PE; unusual-site DVT; strong family history of thrombotic disease; pregnancy or OC-associated DVT; first- and second-degree relatives of early-onset DVT; targeted pre-OC testing for those with personal/family DVT history; pediatric arterial ischemic stroke.
    • Special coverage: plasma testing for protein C and protein S meets criteria for warfarin-induced skin necrosis and neonatal purpura fulminans.
    Prior Authorization

    Prior authorization for non-indicated thrombophilia testing

    Prior authorization may be required when thrombophilia testing is requested outside the policy’s recommended indications (for example, asymptomatic population screening or prenatal screening). Requests for tests outside specified clinical scenarios may not meet coverage criteria.

    Ordering Requirements

    Note

    Order tests consistent with listed indications and timing

    Align ordering with the policy's listed clinical indications and ensure timing criteria are met (including deferral until ≥6 weeks after an acute event); targeted testing prior to OC administration is covered when there is a personal or family history of DVT.

    • Targeted pre‑OC testing is listed under III.f when personal or family history of DVT exists.
    Note

    Order tests according to clinician assessment and guideline‑specified scenarios

    Order testing based on clinician assessment in the specified clinical scenarios identified by guideline bodies (e.g., VTE history, strong family history, pregnancy or postpartum VTE, OC/HRT considerations, pediatric arterial ischemic stroke); avoid routine screening in asymptomatic individuals.

    • ACMG and ACOG recommendations outline appropriate scenarios for testing and contexts where screening is not recommended.

    Frequency Limits

    inv-46: Protein C, Protein S, Antithrombin III
    Timing relative to acute eventPerform plasma testing for protein C, protein S, and antithrombin III at least 6 weeks after the acute thrombotic event.
    Anticoagulant statusSpecimen should be collected while the patient is not taking anticoagulants.
    RationaleAcute thrombosis and anticoagulant therapy can alter protein levels and affect assay interpretation.
    inv-47: Protein C, protein S, antithrombin, factor VIII
    Repeat testing recommendationRepeat non‑DNA tests (e.g., protein C, protein S, antithrombin, factor VIII) 4–6 weeks after the acute event, and up to 6 months for some factors (eg, factor VIII).
    Pediatric considerationNon‑DNA tests in children may need repetition when the child is older due to developmental variability in levels.

    Definitions

    inv-36: VTE / DVT / PE
    VTE definitionVenous thromboembolism (VTE) includes deep vein thrombosis (DVT) and pulmonary embolism (PE).
    DVT definitionDeep vein thrombosis (DVT) is a thrombus in a deep vein.
    PE definitionPulmonary embolism (PE) is obstruction of the pulmonary artery or its branches by thrombus.
    inv-22: aPC resistance / Factor V Leiden (FVL)
    DefinitionFactor V Leiden (FVL; G1691A) causes resistance to activated protein C, reducing anticoagulant activity.
    Detection methodsDetected by genotyping or by functional activated protein C (aPC) resistance assays; functional assays may require confirmatory genetic testing.

    Background

    Thrombosis encompasses both venous events (deep vein thrombosis and pulmonary embolism) and arterial thrombosis. Thrombophilias are hereditary or acquired abnormalities that increase thrombosis risk; common inherited factors include Factor V Leiden, prothrombin G20210A, and deficiencies of protein C, protein S, and antithrombin. Acquired risk factors include surgery, immobilization, malignancy, pregnancy, oral contraceptive use, central venous catheters, and antiphospholipid syndrome. Interpretation of some assays (for example, aPC resistance) can be affected by anticoagulant therapy or the presence of lupus anticoagulant, and genetic confirmation may be required.

    Review / Revision History

    2026-09-15coverage_criteria_revisionLatest

    ACMG guideline update resulted in removal of coverage criterion CC1.f.; former CC1.d. was edited for clarity; editorial removal of a timing note from Note 1.

    2023-09-01coverage_criteria_revision

    Policy revisions removed multiple genetic testing coverage criteria and added CC6 declaring activated protein C (aPC) resistance assay DOES NOT MEET COVERAGE CRITERIA; several CPT/genetic codes were removed from the policy code list.

    2023-01-01
    Policy Summary
    Payerblue cross blue shield - louisiana
    PolicyVenous and Arterial Thrombosis Risk Testing
    Policy CodePolicy AHS - M2041
    Change TypeCoverage criteria updates and code removals (material and editorial changes)
    Effective DateSep 15, 2026
    Last ReviewSep 15, 2026
    Next Review DateSep 15, 2026
    Key ActionOrder protein C, protein S, and antithrombin III plasma testing only for specified clinical indications and perform testing ≥6 weeks after an acute event while the patient is off anticoagulants.
    SourceLink
    On This Page
    Coverage CriteriaCovered IndicationsNot Covered / ExclusionsCoding and Procedure CodesProvider Actions and Prior AuthorizationOrdering RequirementsFrequency LimitsDefinitionsBackgroundReview / Revision History
    Warfarin-induced skin necrosis / neonatal purpura fulminans: Plasma testing for protein C deficiency and protein S deficiency MEETS COVERAGE CRITERIA for individuals with warfarin-induced skin necrosis or infants with neonatal purpura fulminans.

    inv-43: Testing for Factor V Leiden and prothrombin G20210A — covered per ACMG/selected ASH scenarios

    Testing for Factor V Leiden and prothrombin G20210A MEETS COVERAGE CRITERIA when ACMG-recommended indications are present:

    ACMG-recommended covered scenarios: VTE at unusual sites (eg, cerebral, splanchnic); VTE provoked by pregnancy/postpartum; VTE associated with OCs; personal history of VTE with positive family history in first- or second-degree relative or one first-degree relative with early-onset VTE; individuals with low APC resistance activity.

    Per ACMG guidance

    ASH scenarios where testing may guide duration: In select scenarios ASH suggests testing to guide anticoagulant duration (eg, VTE provoked by nonsurgical major transient/hormonal risks; CVT or splanchnic venous thrombosis when anticoagulation discontinuation is being considered).

    Per ASH guidance

    inv-44: Thrombophilia panel testing to guide anticoagulation duration

    Thrombophilia panel testing to inform anticoagulation duration is covered in select scenarios per ASH conditional recommendations:

    ASH scenarios to consider panel testing: Patients with VTE provoked by nonsurgical major transient or hormonal risk factors who have completed primary short-term treatment; patients with cerebral venous thrombosis (CVT) or splanchnic venous thrombosis in settings where anticoagulation would otherwise be discontinued — testing may guide duration of anticoagulation.

    ASH conditional recommendations

    ASH recommendations against routine use: ASH suggests not performing thrombophilia testing to guide duration for many unprovoked, surgically provoked, or unspecified VTE cases (conditional recommendations based on very low certainty).

    ASH guidance

    inv-45: Thrombophilia evaluation in contexts referenced by guideline bodies

    Thrombophilia evaluation is covered in contexts referenced by guideline bodies and noted in the policy revision history:

    Endocrine Society recommendation: The Endocrine Society recommends thrombophilia testing for transgender individuals with a family history of VTE prior to initiating hormone therapy; clinicians should monitor estradiol levels to avoid supraphysiologic concentrations (recommended upper physiologic range 100–200 pg/mL).<= 100-200 pg/mL
    Policy-specified plasma testing: Plasma testing for protein C and protein S is indicated and meets coverage criteria for warfarin-induced skin necrosis or neonatal purpura fulminans as documented in the Review/Revision History.
    Clinical action impliedMonitor serum estradiol during estrogen therapy to maintain levels ≤100–200 pg/mL.
    • Policy emphasizes testing only in specified scenarios and notes routine/population or prenatal screening is not indicated.
    • Prior auth may be used to manage non-indicated requests.
    Billing Rule

    Procedure code considerations — use listed CPT codes on requests

    When submitting claims or prior authorization requests, reference the policy’s listed CPT procedure codes for plasma clotting inhibitor and protein testing; prior authorization or billing guidance should use these codes when applicable.

    • Example CPT codes listed: 85300 (ATIII activity), 85301 (ATIII antigen), 85302 (Protein C antigen), 85303 (Protein C activity), 85305 (Protein S total), 85306 (Protein S free), 85307 (APC resistance assay).
    • Note: policy revision removed several CPT/genetic codes in prior updates per the Review/Revision History.
    Step Therapy

    Ordering sequence & timing — defer testing ≥6 weeks and off anticoagulants

    Do not order protein C, protein S, or antithrombin III plasma testing during the acute thrombosis phase; collect specimens at least six weeks after the acute thrombotic event and while the patient is not taking anticoagulants when possible.

    • Note 1: perform plasma testing ≥6 weeks after the acute thrombotic event and while the patient is not taking anticoagulants.
    • Timing guidance aligns with covered-indication language requiring deferred testing after an acute event.
    Step Therapy

    D-dimer as initial step — follow positive result with imaging

    Use D-dimer as the initial step to exclude PE or DVT in populations with appropriate pretest probability per ASH recommendations; a positive D-dimer should prompt imaging (eg, CTPA or VQ for PE; proximal/whole-leg ultrasound for DVT) rather than being used alone to establish diagnosis.

    • ASH recommends starting with D-dimer to exclude PE or DVT in low or intermediate pretest probability populations, followed by imaging for patients requiring additional testing.
    • ASH recommends against using a positive D-dimer alone to diagnose PE or DVT.
    Step Therapy

    Step therapy — no additional step therapy rules specified

    The policy excerpt does not specify any step therapy rules for thrombophilia testing beyond timing and sequencing guidance; there are no additional mandated step interventions listed.

    • Review/Revision History and step therapy modules state no formal step therapy rules are specified in this excerpt.
    Documentation Required

    Timing & specimen conditions — collect ≥6 weeks post-event and off anticoagulants

    Specimen timing and conditions must be documented: plasma testing for protein C, protein S, and antithrombin III should be performed at least six weeks after an acute thrombotic event and while the patient is not receiving anticoagulants.

    • Ensure the specimen is collected off anticoagulant therapy when feasible and after the recommended waiting period post-event.
    Documentation Required

    Documentation requirement — record clinical scenario and event timing

    Document the clinical scenario and timing relative to the acute event when ordering tests: include indication (type of VTE or unusual site), whether VTE was provoked or unprovoked, family history, pregnancy status, and current contraceptive or HRT use, and note the date of the acute event to confirm appropriate deferment interval.

    • Guidelines recommend deferring or repeating protein C/S/antithrombin testing 4–6 weeks (or longer for some factors) after acute stroke/event; record timing in documentation.
    • Include family history and reproductive/medication status per ACMG and ACOG context when relevant.
    Denial Risk

    aPC resistance assay denial risk — assay does not meet coverage (CC6)

    Requests for activated protein C (aPC) resistance assay will be denied because the assay does not meet coverage criteria (CC6); do not submit claims for aPC resistance assay as a covered plasma test under this policy.

    • Policy explicitly states: 'For all situations, activated protein C (aPC) resistance assay DOES NOT MEET COVERAGE CRITERIA.'
    • Review/Revision History documents introduction of CC6 designating aPC resistance assay as not covered.
    Denial Risk

    Denial triggers — avoid excluded assays and non-covered indications

    Denial triggers include requests for testing outside covered indications—examples specifically called out are aPC resistance assay, venous thrombosis risk testing for superficial venous thrombosis (including superficial thrombophlebitis and varicosities), and DVT risk testing as part of a pre-transplant evaluation; ordering tests for these indications may result in denial.

    • Do not order tests for superficial venous thrombosis risk assessment or as part of pre-transplant evaluation—these do not meet coverage criteria.
    • Avoid ordering aPC resistance assay because it is explicitly excluded from coverage.
    Note
    Note
    Billing Rule

    Ensure LDTs are CLIA‑validated and performed in‑house

    Laboratory‑developed tests (LDTs) used for thrombophilia testing are CLIA high‑complexity tests that laboratories must validate and perform in‑house; ensure ordered LDTs meet CLIA requirements.

    • LDTs are regulated under CLIA '88 as high‑complexity tests and require in‑house validation.
    When to deferDefer or repeat testing during acute stroke/event because protein levels may be altered in the acute phase.
    inv-48: No frequency limits specified in this excerpt
    Frequency limits in policy excerptNo frequency limits are specified in this excerpt.
    ImplicationPolicy does not define routine repeat interval beyond event‑based or guideline‑directed recommendations in the provided text.
    Reference to revision historyReview/Revision History present but does not add frequency limits in the excerpt.
    Clinical suspicionOften suspected in patients with VTE at young age (<50), VTE in unusual sites, or recurrent VTE.
    inv-38: Factor II c.*97G>A (prothrombin G20210A)
    Variant identityFactor II c.*97G>A is the prothrombin G20210A mutation referenced by ACMG.
    PathophysiologyThis gain‑of‑function mutation increases prothrombin levels, leading to higher thrombin and fibrin generation.
    Testing contextACMG recommends testing for this variant in specified clinical scenarios (eg, VTE at unusual sites, pregnancy‑related VTE).
    inv-39: MTHFR testing
    Policy stanceTesting for MTHFR variants is not supported for thrombophilia assessment due to lack of correlation with adverse pregnancy outcomes.
    ACMG positionACMG does not support MTHFR variant testing for thrombophilia assessment; statement reaffirmed in 2020 and 2025.
    Coverage implicationMTHFR variant testing is listed as not indicated for prenatal or population screening in this policy.
    inv-40: Physiological estradiol range
    Recommended upper physiologic estradiol concentration100-200 pg/mL
    PurposeMaintain estradiol ≤100–200 pg/mL in those receiving estrogen therapy to avoid supraphysiological concentrations linked to increased VTE risk.
    Guideline sourceEndocrine Society clinical guidance on hormone therapy for transgender individuals.
    coverage_criteria_revision

    Under CC2 for plasma testing, 'recurrent deep vein thrombosis' was removed as a subcriterion; CPT code 0278U was added earlier in the policy history before its later removal.

    2022-05-15policy_implementation

    Initial policy implementation recorded.